The world’s first lung cancer vaccine treatment from Cuba is now being used in several other Latin American countries and is the first Cuban patented drug to be allowed to undergo clinical trials at a U.S. cancer research institute.
CimaVax-EGF is a Cuban developed vaccine aimed at preventing the recurrence of the disease. Early results were so positive that in 2016, the Roswell Park Cancer Institute in the United States persuaded the U.S. government to allow it to test the vaccine.
Contrary to other lung cancer fighting drugs on the market, CimaVax does not work on attacking the cancer cells but instead it helps the body generate its own immune system in a way that starves the cancer and stops it from growing.
Patients still have to complete a course of chemo or radio therapy before being eligible to receive the vaccines.